Critical Reviews in Oncology / Hematology

Slides:

Advertisements

Similar presentations

Date of download: 6/22/2016 From: Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced.

Advertisements

Umesh K. Narta, Shamsher S. Kanwar, Wamik Azmi

Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review Cloé Brami, Ting Bao, Gary Deng Critical.

Comparative systematic review and meta-analysis of compression modalities for the promotion of venous ulcer healing and reducing ulcer recurrence Karen.

Association Between Postoperative Acute Kidney Injury and Duration of Cardiopulmonary Bypass: A Meta-Analysis Avinash B. Kumar, MD, FCCP, Manish Suneja,

Nicoletta Colombo, Martin Gore

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Yun Hyung Koog, Jin Su Lee, Hyungsun Wi

Does statin therapy reduce plasma VEGF levels in humans

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

Critical Reviews in Oncology / Hematology

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer Sandro Pignata, Enrico.

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey Lazzaro Repetto Critical.

Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review.

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials Gustavo Arruda Viani,

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC) Giorgio Arcangeli,

Abhimanyu Ghose, Ria Kundu, Tahir Latif

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

P. Therasse, S. Carbonnelle, J. Bogaerts

TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct.

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

Critical Reviews in Oncology / Hematology

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello Critical.

Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis of.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants: an updated meta-analysis of 20.

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis Meletios Athanasios.

The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence Hashem B. El–Serag, Howard Hampel, Fariba.

Masatsugu Hamaji, MD, Syed Osman Ali, MD, Bryan M. Burt, MD

The Role of Systematic Reviews and Meta-analysis in Dermatology

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Nikolaos P. Polyzos, M. D. , Christina I. Messini, M. D. , Evangelos G

A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both Nadia Aissaoui, Edith Martins,

Adenomyosis and reproductive performance after surgery for rectovaginal and colorectal endometriosis: a systematic review and meta-analysis Paolo Vercellini,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Comparative systematic review and meta-analysis of compression modalities for the promotion of venous ulcer healing and reducing ulcer recurrence Karen.

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Effect of combining tramadol and morphine in adult surgical patients: a systematic review and meta-analysis of randomized trials V. Martinez, L. Guichard,

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Loss of natural abutment teeth with cast copings retaining overdentures: a systematic review and meta-analysis Alexander Mercouriadis-Howald, Noemie.

Aaron M. Drucker, Patrick Fleming, An-Wen Chan

Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials Kannan Sridharan,

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta- analysis of randomized placebo-controlled trials E.M. Bartels,

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Hidde Jongsma, MD, Joost A. Bekken, MD, George P

Role of therapeutic hypothermia in improving outcome after traumatic brain injury: a systematic review A.P. Georgiou, A.R. Manara British Journal of.

Volume 375, Issue 9719, Pages (March 2010)

Volume 152, Issue 1, Pages (January 2019)

Masatsugu Hamaji, MD, Syed Osman Ali, MD, Bryan M. Burt, MD

A Meta-Analysis of Postoperative Radiotherapy for Thymic Carcinoma

D. Fletcher, V. Martinez British Journal of Anaesthesia

Helen Barraclough, MSc, Ramaswamy Govindan, MD

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Effects of Smartphone-Based Mobile Learning in Nursing Education: A Systematic Review and Meta-analysis Ju Hee Kim, Hanjong Park Asian Nursing Research

Reply Journal of Vascular Surgery

High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis.

Systematic review on the association between calcification in carotid plaques and clinical ischemic symptoms Robert M. Kwee, MD Journal of Vascular.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Volume 154, Issue 1, Pages (July 2019)

Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.

Presentation transcript:

Critical Reviews in Oncology / Hematology Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials Giuseppe Lombardi, Ardi Pambuku, Luisa Bellu, Miriam Farina, Alessandro Della Puppa, Luca Denaro, Vittorina Zagonel Critical Reviews in Oncology / Hematology Volume 111, Pages 94-102 (March 2017) DOI: 10.1016/j.critrevonc.2017.01.018 Copyright © 2017 Elsevier B.V. Terms and Conditions

Fig. 1 The PRISMA flowchart summarizing the process for the identification of the eligible studies. Critical Reviews in Oncology / Hematology 2017 111, 94-102DOI: (10.1016/j.critrevonc.2017.01.018) Copyright © 2017 Elsevier B.V. Terms and Conditions

Fig. 2 Hazard Ratios for overall survival (A) and progression-free survival (B). ES: effect size (HR); CI: confidence interval; W: weight; Sig: statistical significance; N: number of patients; ced: cediranib; lom: lomustine; cil: cilengitide; intCil: intensive cilengitide; bev: bevacizumab. Critical Reviews in Oncology / Hematology 2017 111, 94-102DOI: (10.1016/j.critrevonc.2017.01.018) Copyright © 2017 Elsevier B.V. Terms and Conditions

Fig. 3 Funnel plot scatter plots of antiangiogenic drug effects estimated from individual studies (horizontal axis) against the study size (vertical axis). The symmetric inverted funnel shape and the fill and trim analysis (result in black) suggest that publication bias in unlikely. A: effect size (HR) for overall survival; B: effect size (HR) for progression-free survival. Critical Reviews in Oncology / Hematology 2017 111, 94-102DOI: (10.1016/j.critrevonc.2017.01.018) Copyright © 2017 Elsevier B.V. Terms and Conditions

Fig. 4 Overall survival by subgroups: (A) Bevacizumab or other antiangiogenic drugs; (B) Antiangiogenic drugs as first or second-line treatment; (C) Antiangiogenic drugs alone or in association to cytotoxic treatment; (D) Bevacizumab alone or in association to cytotoxic drugs; (E) Bevacizumab as first or second-line treatment. ES: effect size (HR for OS); CI: confidence interval; W: weight; Sig: statistical significance; N: number of patients; ced: cediranib; lom: lomustine; cil: cilengitide; intCil: intensive cilengitide; bev: bevacizumab. Critical Reviews in Oncology / Hematology 2017 111, 94-102DOI: (10.1016/j.critrevonc.2017.01.018) Copyright © 2017 Elsevier B.V. Terms and Conditions

Fig. 5 Progression-free survival by subgroups: (A) Bevacizumab or other antiangiogenic drugs; (B) Antiangiogenic drugs as first or second-line treatment; (C) Antiangiogenic drugs alone or in association to cytotoxic treatment; (D) Bevacizumab alone or in association to cytotoxic drugs; (E) Bevacizumab as first or second-line treatment; (F) Antiangiogenic drugs (except for bevacizumab) alone or in association to cytotoxic treatment. ES: effect size (HR for OS); CI: confidence interval; W: weight; Sig: statistical significance; N: number of patients; ced: cediranib; lom: lomustine; cil: cilengitide; intCil: intensive cilengitide; bev: bevacizumab. Critical Reviews in Oncology / Hematology 2017 111, 94-102DOI: (10.1016/j.critrevonc.2017.01.018) Copyright © 2017 Elsevier B.V. Terms and Conditions